Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

This is a prospective, non-randomized, clinical observational cohort study. The subjects are the advantageous population for functional cure of hepatitis B in HIV/HBV co-infected patients . Depending on whether interferon therapy is used in the real world , the patients are divided into two groups: the ART combined with interferon group and the ART alone group, with 30 cases in each group. Hepatitis B surface antigen seroclearance rate and seroconversion rate will be observed during the study period.

Inclusion criteria

• Age 18-65 years old, gender unrestricted.
• Meeting the People's Republic of China Health Industry Standard (WS293-2008) - "AIDS and HIV Infection Diagnostic Criteria", confirmed as HIV-1 infected.
• HBsAg positive for more than 6 months.
• At least 1 year of ART treatment prior to screening, and currently undergoing ART treatment with HBsAg <1000IU/mL, HBeAg negative, HBV DNA <100IU/ml, CD4+T lymphocyte count >200 cells/μL and HIV-RNA<20 copies/ml.

Exclusion criteria

• Pregnant, nursing, planning pregnancy, or with severe mental disorders or uncontrolled epilepsy.
• Co-infected with Hepatitis A, C, D, or E viruses.
• With other chronic liver diseases like autoimmune hepatitis, drug-induced hepatitis, alcoholic hepatitis, genetic metabolic liver diseases, or moderate to severe fatty liver.
• With autoimmune diseases like rheumatoid arthritis, psoriasis, or lupus.
• Post organ transplant, planning organ transplant, diagnosed or suspected of liver cancer or other malignant tumors, or undergoing immunosuppressive treatment.
• With severe diseases of heart, lungs, kidneys, brain, retinal disorders, or uncontrolled hypertension or diabetes.
• Excessive alcohol (average daily alcohol intake >40g for men, >20g for women) or drug users.
• Participated in other interventional trials within the last three months, or other situations deemed inappropriate for inclusion by researchers.